CHOOSE IXINITY®

Offer your patients predictable bleed control and an established safety profile

*Previously treated patients (PTPs) receiving routine prophylactic treatment of 40 IU/kg to 70 IU/kg of IXINITY twice weekly demonstrated a median annualized spontaneous bleeding rate (AsBR) of 0, and a median total annualized bleeding rate (ABR) of 1.52.2

The efficacy (n=68) and safety (n=77) of IXINITY have been evaluated in a prospective, open-label, uncontrolled, multicenter trial in which previously treated patients between 7 and 64 years of age received IXINITY in either a routine or on demand regimen, including 55 patients with more than 50 exposure days and 45 of those patients with more than 100 exposure days.2

*Previously treated patients (PTPs) receiving routine prophylactic treatment of 40 IU/kg to 70 IU/kg of IXINITY twice weekly demonstrated a median annualized spontaneous bleeding rate (AsBR) of 0, and a median total annualized bleeding rate (ABR) of 1.52.2

The efficacy (n=68) and safety (n=77) of IXINITY have been evaluated in a prospective, open-label, uncontrolled, multicenter trial in which previously treated patients between 7 and 64 years of age received IXINITY in either a routine or on demand regimen, including 55 patients with more than 50 exposure days and 45 of those patients with more than 100 exposure days.2

Watch as real patients share their IXINITY IXperience™

Watch as real patients share their IXINITY IXperience™

Find out if IXINITY is right for your patients

EXPLORE MORE ABOUT IXINITY

Reference: 1. IXINITY [coagulation factor IX (recombinant)] prescribing information. Chicago, IL: Medexus Pharma, Inc.; February 2021. 2. Collins PW, Quon DVK, Makris M, et al. Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated Haemophilia. 2018;24:104-112. 3. Data on file. Chicago, IL: Medexus Pharma, Inc.